CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bassing, C. H.
Right arrow Articles by Wang, X. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bassing, C. H.
Right arrow Articles by Wang, X. F.

Cell Growth & Differentiation, Vol 9, Issue 3 223-228, Copyright © 1998 by American Association of Cancer Research


ARTICLES

FKBP12 is not required for the modulation of transforming growth factor beta receptor I signaling activity in embryonic fibroblasts and thymocytes

CH Bassing, W Shou, S Muir, J Heitman, MM Matzuk and XF Wang
Department of Pharmacology & Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710, USA.

Transforming growth factor beta (TGF-beta) signals through a heteromeric complex of type I and type II transmembrane serine-threonine kinases. Recent evidence suggests that the immunophilin FKBP12 modulates the activity of the type I receptor, based on data that immunosuppressive drugs that disrupt FKBP12 binding to the type I receptor enhance TGF-beta signaling in mink lung epithelial cells, and overexpression of FKBP12 inhibits type I receptor phosphorylation by the type II receptor. To determine the physiological relevance of the FKBP12-TGF-beta receptor I interaction, we investigated whether disruption of this interaction affects TGF-beta-signaling in primary mouse embryo fibroblasts and thymocytes. We found that the addition of excess drugs had no effect on either TGF-beta-mediated transcriptional responses or growth inhibition. Dose-response curves for TGF-beta-mediated signaling in primary fibroblasts and thymocytes isolated from either wild-type or FKBP12-deficient mice were identical. Taken together, our results indicate that FKBP12 does not play a unique physiological role in TGF-beta signaling in primary fibroblasts and thymocytes.


This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
J. A. Garcia and D. Danielpour
Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies
Mol. Cancer Ther., June 1, 2008; 7(6): 1347 - 1354.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
T Yamaguchi, A Kurisaki, N Yamakawa, K Minakuchi, and H Sugino
FKBP12 functions as an adaptor of the Smad7-Smurf1 complex on activin type I receptor.
J. Mol. Endocrinol., June 1, 2006; 36(3): 569 - 579.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
J. Nagano, K. Iyonaga, K. Kawamura, A. Yamashita, H. Ichiyasu, T. Okamoto, M. Suga, Y. Sasaki, and H. Kohrogi
Use of tacrolimus, a potent antifibrotic agent, in bleomycin-induced lung fibrosis.
Eur. Respir. J., March 1, 2006; 27(3): 460 - 469.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. Bommireddy, V. Saxena, I. Ormsby, M. Yin, G. P. Boivin, G. F. Babcock, R. R. Singh, and T. Doetschman
TGF-{beta}1 Regulates Lymphocyte Homeostasis by Preventing Activation and Subsequent Apoptosis of Peripheral Lymphocytes
J. Immunol., May 1, 2003; 170(9): 4612 - 4622.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. Bommireddy, I. Ormsby, M. Yin, G. P. Boivin, G. F. Babcock, and T. Doetschman
TGF{beta}1 Inhibits Ca2+-Calcineurin-Mediated Activation in Thymocytes
J. Immunol., April 1, 2003; 170(7): 3645 - 3652.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
B. Aghdasi, K. Ye, A. Resnick, A. Huang, H. C. Ha, X. Guo, T. M. Dawson, V. L. Dawson, and S. H. Snyder
FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle
PNAS, February 27, 2001; 98(5): 2425 - 2430.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
D. Yao, J. J. E. Dore Jr., and E. B. Leof
FKBP12 Is a Negative Regulator of Transforming Growth Factor-{beta} Receptor Internalization
J. Biol. Chem., April 28, 2000; 275(17): 13149 - 13154.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
J. Massague and Y.-G. Chen
Controlling TGF-beta signaling
Genes & Dev., March 15, 2000; 14(6): 627 - 644.
[Full Text]


Home page
GeneticsHome page
K. J. Dolinski and J. Heitman
Hmo1p, a High Mobility Group 1/2 Homolog, Genetically and Physically Interacts With the Yeast FKBP12 Prolyl Isomerase
Genetics, March 1, 1999; 151(3): 935 - 944.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
B. Aghdasi, K. Ye, A. Resnick, A. Huang, H. C. Ha, X. Guo, T. M. Dawson, V. L. Dawson, and S. H. Snyder
FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle
PNAS, February 27, 2001; 98(5): 2425 - 2430.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1998 by the American Association of Cancer Research.